Bexagliflozin Efficacy and Safety Trial
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1700 participants.
Also called NCT02558296
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,700 participants
- Sponsor
- Registry
-
NCT02558296
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Czechia, Denmark, Mexico, Netherlands, Poland, Russia, South Korea, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT02558296. Randomized; quadruple masking; primary purpose treatment. Start 2015-10 (actual); primary completion 2018-08 (actual). Results posted on 2021-07-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Bexagliflozin Efficacy and Safety Trial
- Acronym
- BEST
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Bexagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Theracos
Record details
- Record id
cardio:ct-nct02558296- Content hash
f47d796ff2c6144a1ceaf28484e95dcac2a1dae69ff9aad9989fc6d6feb67129